Abstract
This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by facilitating drug transport across the blood–brain barrier. Despite substantial advancements in targeted delivery and vaccine efficacy, challenges remain in scalability, regulatory approval, and transitioning from preclinical studies to clinical applications. The future of chitosan-based nanomedicines hinges on advancing clinical trials, fostering interdisciplinary collaboration, and innovating in nanoparticle design to overcome these hurdles and realize their therapeutic potential.
| Original language | English |
|---|---|
| Article number | 746 |
| Journal | Pharmaceutics |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2024 |
Bibliographical note
Publisher Copyright:© 2024 by the authors.
Funding
This research received no external funding.
ASJC Scopus Subject Areas
- Pharmaceutical Science
Keywords
- chitosan nanoparticles
- clinical translation
- intranasal drug delivery
- neurodegenerative disorders
- regulatory challenges
Disciplines
- Pharmacy and Pharmaceutical Sciences